+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 75 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.

Age: 18Years - 80YearsAll GendersPhase 3
38 locations
S

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and behavior of GT719 Injection, a biological treatment, in adults with relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma and B-acute lymphoblastic leukemia. This early phase 1 clinical trial includes a dose escalation and an expansion phase. The study will enroll 34 participants to understand how the treatment works in these blood cancers. Participants will receive the GT719 Injection as the study treatment. The trial involves a single treatment group receiving this injection to assess its effects and safety. The study includes monitoring after the infusion, focusing on adverse events, dose tolerance, and the behavior of infused cells over time. During the study, participants will be closely observed for any side effects and treatment responses. Researchers will assess adverse events within 28 days and monitor overall response, duration of response, survival rates, and infused cell activity up to 12 months. Participants will undergo medical exams, lab tests, and imaging as needed to track these outcomes and ensure safety throughout the trial, which runs until December 2027.

Age: 18Years - 75YearsAll GendersEarly Phase 1
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of LBL-024 combination therapy for patients with advanced non-small cell lung cancer NSCLC, a type of advanced solid tumor. This open-label, multicenter Phase II study aims to understand how well LBL-024 works when given alongside other cancer drugs. The study includes four groups of participants to assess different drug combinations and treatment approaches. Participants receive LBL-024 combined with drugs such as docetaxel, bevacizumab, pemetrexed, carboplatin, or paclitaxel through intravenous infusion. Each group starts with a 21-day safety observation period to monitor tolerability, followed by randomized assignment to specific treatment arms if safety is confirmed. Some groups continue with maintenance therapy using LBL-024 or other drugs after initial combination treatment. During the trial, participants undergo regular assessments including physical exams, laboratory tests, and imaging to monitor tumor response and safety. Researchers measure outcomes like objective response rate, disease control rate, and duration of response. Monitoring continues through a follow-up period after treatment ends to evaluate lasting effects and drug safety. The study plans to enroll up to 250 participants aged 18 to 75 years.

Age: 18Years - 75YearsAll GendersPhase 2
24 locations
P

Actively Recruiting

Researchers are evaluating TQB2102, an antibody-drug conjugate designed to target Human Epidermal Growth Factor Receptor 2 HER2 in patients with locally advanced or metastatic non-small cell lung cancer who have HER2 gene abnormalities. This Phase 2 study aims to assess the effectiveness and safety of TQB2102, which combines targeted antibody action with a potent drug payload that is normally too toxic for general use. Participants receive TQB2102 through intravenous infusion every three weeks, with each treatment cycle lasting 21 days. Some participants will receive TQB2102 alone, while others will receive TQB2102 combined with Benmelstobart, another intravenous drug targeting programmed death ligand-1 PD-L1. Both treatments are given over multiple cycles to evaluate their effects. During the study, participants will be closely monitored through various assessments including measuring tumor response over up to eight months, tracking survival, and recording any adverse events from the start of treatment until 28 days after the last dose. Researchers will also check for immune responses to the drug at several points during and after treatment. The total participation may last up to 18 months to gather comprehensive safety and effectiveness data.

Age: 18Years - 75YearsAll GendersPhase 2
25 locations
A

Actively Recruiting

Researchers are evaluating BB-1705, an antibody-drug conjugate, in patients with locally advanced or metastatic solid tumors that have progressed after standard treatments. This Phase I study has two parts a dose-escalation phase to find the safest and most effective dose, and a cohort expansion phase to further assess safety, how the drug moves through the body, and its early anti-tumor effects. BB-1705 is given as an intravenous infusion every three weeks for up to eight cycles. During the dose-escalation phase, different doses are tested to find the maximum tolerated dose, followed by a cohort expansion phase where selected doses are given to more patients to monitor safety and preliminary effectiveness. The study is open label and non-randomized. Participants will have regular visits for safety checks, blood tests, and tumor assessments using imaging every 6 to 9 weeks for up to two years. Researchers will closely track side effects, drug levels, immune responses, tumor response, and progression-free survival. The total study duration includes treatment cycles and follow-up for adverse events and clinical outcomes.

Age: 18Years - 78YearsAll GendersPhase 1
7 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
P

Actively Recruiting

Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.

Age: 18Years +All GendersPhase 1Phase 2
107 locations
E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are evaluating HLX43, an anti-PD-L1 antibody linked to a potent DNA topoisomerase I inhibitor, in patients with recurrent or metastatic Nasopharyngeal Carcinoma NPC who have not responded to or cannot tolerate second-line therapies. This phase II open-label study aims to find the appropriate dose and assess the safety, tolerability, and effectiveness of HLX43 in this patient group. Participants are randomly assigned to one of three HLX43 dose groups. The drug is given through intravenous infusion every three weeks. Treatment continues as long as patients tolerate it well and the disease remains controlled, stopping only if the disease progresses, intolerable side effects occur, another anti-cancer therapy is started, consent is withdrawn, or death occurs. During the study, patients will undergo regular assessments including tumor evaluations to measure response and progression, safety monitoring for adverse effects, and tissue sample collection for PD-L1 expression analysis. The main outcomes measured are the overall response rate within 24 weeks and progression-free survival up to 12 months. Patients will be followed for safety and survival for up to 18 months after treatment starts.

Age: 18Years +All GendersPhase 2
15 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations

1-10 of 75

1